
The Federal Joint Committee is expanding the breast cancer early detection program to include women aged 45 to 49.
AI-generated summary
Mammography screening is a statutory service for the early detection of breast cancer. Previously, the program was intended for women aged 50 to 75.
Berlin. In the future, younger women aged 45 to 49 will also be able to take part in mammography screening. The Federal Joint Committee, the highest decision-making body for the individual benefits of statutory health insurance (GKV), lowered the lower age limit for participation in the breast cancer screening program. There should be a transition period to make adjustments easier. Newly eligible women are expected to be able to register for an examination appointment themselves from August 1, 2027. According to the Federal Committee, you will probably receive personal invitations from January 2028.
Currently, all women between the ages of 50 and 75 can take part in the mammography screening program, which is around 14.5 million women, according to the committee. By opening it up to younger women aged 45 and over, 2.5 million more women should be able to benefit from the health insurance benefit.
“Early detection only works well if signs of illness are reliably recognized and ‘false alarms’ occur as rarely as possible,” said committee member Bernhard van Treeck. “With this in mind, we hope we have made a good decision.” The decision is now being examined by the Federal Ministry of Health. If there are no legal objections to the resolutions, they will come into force on August 1, 2027. From this date onwards, women can take part in the screening.
AI outlook — possibilities, not facts
The new regulation will come into force on August 1, 2027 after review by the ministry.
Likely · Within months
After the death of a 34-year-old water ski instructor from a Naegleria fowleri infection, Yucatán has closed six artificial lakes in Mérida where the parasite was detected. Infections are rare but usually fatal.

The European Medicines Agency (EMA) recommends approval of daraxonrasib (trade name Rasonque) for patients with metastatic pancreatic cancer who have failed prior treatment. Studies show significantly longer survival times.

The EMA recommends EU approval of the drug daraxonrasib (trade name Rasonque) for patients with metastatic pancreatic cancer. The drug from the manufacturer Revolution Medicines is intended to significantly extend survival time in patients with previous treatment.

The Bundestag has passed a comprehensive reform of emergency care. Through better interlinking of the numbers 116117 and 112 as well as the introduction of integrated emergency centers, patients should be directed more efficiently to the appropriate level of care.

The average additional contribution rate for statutory health insurance companies will remain at 2.9 percent in 2027. Despite this stability, costs rise for high earners due to a higher contribution assessment limit, while those with private insurance expect premium increases.

The GKV estimators expect a stable average additional contribution of 2.9 percent for 2027. However, experts warn of short-term effects and call for far-reaching structural reforms to avoid impending deficits by 2035.